Construction of Predictive Models for Cancer-specific Survival of Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Results from a Multicenter Retrospective Study

被引:6
|
作者
Nishiyama, Naotaka [1 ]
Kitamura, Hiroshi [1 ]
Hotta, Hiroshi [2 ]
Takahashi, Atsushi [3 ]
Yanase, Masahiro [4 ]
Itoh, Naoki [5 ]
Tachiki, Hitoshi [6 ]
Miyao, Noriomi [7 ]
Matsukawa, Masanori [8 ]
Kunishima, Yasuharu [9 ]
Taguchi, Keisuke [10 ]
Masumori, Naoya [1 ]
机构
[1] Sapporo Med Univ, Dept Urol, Sch Med, Sapporo, Hokkaido 0608543, Japan
[2] Asahikawa Red Cross Hosp, Dept Urol, Asahikawa, Hokkaido, Japan
[3] Hakodate Goryoukaku Hosp, Dept Urol, Hakodate, Hokkaido, Japan
[4] Sunagawa City Med Ctr, Dept Urol, Sunagawa, Japan
[5] NTT East Japan Sapporo Hosp, Dept Urol, Sapporo, Hokkaido, Japan
[6] Steel Mem Muroran Hosp, Dept Urol, Muroran, Hokkaido, Japan
[7] Muroran City Gen Hosp, Dept Urol, Muroran, Hokkaido, Japan
[8] Takikawa Municipal Hosp, Dept Urol, Takikawa, Hokkaido, Japan
[9] Hokkaido Social Work Assoc Obihiro Hosp, Dept Urol, Obihiro, Hokkaido, Japan
[10] Oji Gen Hosp, Dept Urol, Tomakomai, Japan
关键词
non-muscle-invasive bladder cancer; bacillus Calmette-Guerin; BCG failure classification; UROTHELIAL CARCINOMA; PROGNOSTIC-FACTORS; RISK; MANAGEMENT; FAILURE; TUMORS; PROGRESSION; RECURRENCE; THERAPY; DISEASE;
D O I
10.1093/jjco/hyu119
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aims of this study were to clarify the prognostic factors and to validate the bacillus Calmette-Guerin failure classification advocated by Nieder et al. in patients with non-muscle-invasive bladder cancer who had intravesical recurrence after bacillus Calmette-Guerin therapy. Methods: Data from 402 patients who received intravesical bacillus Calmette-Guerin therapy between January 1990 and November 2011 were collected from 10 institutes. Among these patients, 187 with bacillus Calmette-Guerin failure were analyzed for this study. Results: Twenty-nine patients (15.5%) were diagnosed with progression at the first recurrence after bacillus Calmette-Guerin therapy. Eighteen (62.1%) of them died of bladder cancer. A total of 158 patients were diagnosed with non-muscle-invasive bladder cancer at the first recurrence after bacillus Calmette-Guerin therapy. Of them, 23 (14.6%) underwent radical cystectomy. No patients who underwent radical cystectomy died of bladder cancer during the follow-up. On multivariate analysis of the 135 patients with bladder preservation, the independent prognostic factors for cancer-specific survival were age (>= 70 [P = 0.002]), tumor size (>= 3 cm [P = 0.015]) and the Nieder classification (bacillus Calmette-Guerin refractory [P < 0.001]). In a subgroup analysis, the estimated 5-year cancer-specific survival rates in the groups with no positive, one positive and two to three positive factors were 100, 93.4 and 56.8%, respectively (P < 0.001). Conclusions: Patients with stage progression at the first recurrence after bacillus Calmette-Guerin therapy had poor prognoses. Three prognostic factors for predicting survival were identified and used to categorize patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin into three risk groups based on the number of prognostic factors in each one.
引用
收藏
页码:1101 / 1108
页数:8
相关论文
共 50 条
  • [1] A retrospective study on tolerability and complications of bacillus Calmette-Guerin (BCG) instillations for non-muscle-invasive bladder cancer
    Nummi, Antti
    Jarvinen, Riikka
    Sairanen, Jukka
    Huotari, Kaisa
    SCANDINAVIAN JOURNAL OF UROLOGY, 2019, 53 (2-3) : 116 - 122
  • [2] Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients
    Gontero, Paolo
    Sylvester, Richard
    Pisano, Francesca
    Joniau, Steven
    Eeckt, Kathy Vander
    Serretta, Vincenzo
    Larre, Stephane
    Di Stasi, Savino
    Van Rhijn, Bas
    Witjes, Alfred J.
    Grotenhuis, Anne J.
    Kiemeney, Lambertus A.
    Colombo, Renzo
    Briganti, Alberto
    Babjuk, Marek
    Malmstrom, Per-Uno
    Oderda, Marco
    Irani, Jacques
    Malats, Nuria
    Baniel, Jack
    Mano, Roy
    Cai, Tommaso
    Cha, Eugene K.
    Ardelt, Peter
    Varkarakis, John
    Bartoletti, Riccardo
    Spahn, Martin
    Johansson, Robert
    Frea, Bruno
    Soukup, Viktor
    Xylinas, Evanguelos
    Dalbagni, Guido
    Karnes, R. Jeffrey
    Shariat, Shahrokh F.
    Palou, Joan
    EUROPEAN UROLOGY, 2015, 67 (01) : 74 - 82
  • [3] Prognostic significance of Bacillus Calmette-Guerin failure classification in non-muscle-invasive bladder cancer
    Shirakawa, Hiroshi
    Kikuchi, Eiji
    Tanaka, Nobuyuki
    Matsumoto, Kazuhiro
    Miyajima, Akira
    Nakamura, So
    Oya, Mototsugu
    BJU INTERNATIONAL, 2012, 110 (6B) : E216 - E221
  • [4] The Efficacy of Intravesical Bacillus Calmette-Guerin in the Treatment of Patients with pT1 Stage Non-muscle-invasive Bladder Cancer
    Ajili, Faouzia
    Darouiche, Amine
    Chebil, Mouhamed
    Boubaker, Samir
    ULTRASTRUCTURAL PATHOLOGY, 2013, 37 (04) : 278 - 283
  • [5] The Role of Bacillus Calmette-Guerin in the Treatment of Non-Muscle-Invasive Bladder Cancer
    Gontero, Paolo
    Bohle, Andreas
    Malmstrom, Per-Uno
    O'Donnell, Michael A.
    Oderda, Marco
    Sylvester, Richard
    Witjes, Fred
    EUROPEAN UROLOGY, 2010, 57 (03) : 410 - 429
  • [6] Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer
    Shepherd, Andrew R. H.
    Shepherd, Emily
    Brook, Nicholas R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (03):
  • [7] Intravesical bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: A review
    Saluja, Manmeet
    Gilling, Peter
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (01) : 18 - 24
  • [8] Tumor Multiplicity Is an Independent Prognostic Factor of Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin Immunotherapy
    Ajili, Faouzia
    Manai, Mohamed
    Darouiche, Amine
    Chebil, Mohamed
    Boubaker, Samir
    ULTRASTRUCTURAL PATHOLOGY, 2012, 36 (05) : 320 - 324
  • [9] Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin
    Azuma, Takeshi
    Nagase, Yasushi
    Oshi, Masaya
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (05) : 1113 - 1116
  • [10] Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin Immunotherapy
    Bacon, Jack V. W.
    Muller, David C.
    Ritch, Elie
    Annala, Matti
    Dugas, Sarah G.
    Herberts, Cameron
    Vandekerkhove, Gillian
    Seifert, Helge
    Zellweger, Tobias
    Black, Peter C.
    Bubendorf, Lukas
    Wyatt, Alexander W.
    Rentsch, Cyrill A.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06): : 677 - 686